Iambic prices $150M IPO to fund AI-discovered drug pipeline
What's the deal? Iambic Therapeutics priced its initial public offering at $16.00 per share, selling 9,375,000 shares for expected gross proceeds of $150 million. The clinical-stage company begins trading on the Nasdaq Global Select Market on October 15, 2026, under the ticker "IAM."
The fine print: Iambic is offering all the shares itself, and has granted underwriters a 30-day option to buy an additional 1,406,250 shares at the IPO price. The offering is expected to close on October 16, 2026.
Who's backing it? J.P. Morgan, Jefferies, BofA SecuritiesDealroom has a profile for this one. Try Dealroom →, and Citigroup are acting as joint book-running managers for the offering.
What's the endgame? Iambic uses an AI-driven platform — combining proprietary models with automated chemistry and biology — to discover and develop new medicines. It says the approach helped advance its drug candidate IAM1363 to clinical trials in roughly two years, alongside a broader preclinical pipeline.
The signal: Iambic's listing tests public-market appetite for companies that pitch artificial intelligence as the engine behind drug discovery, a sector where most players remain privately held. A clean debut would give later-stage AI-biotech peers a clearer path to the Nasdaq.
Read more: business.theantlersamerican.com
Image credit: Generated with Gemini
